NHLBI
Working Group Antimicrobial Strategies and Cardiothoracic SurgeryExecutive
SummaryThe National Heart, Lung, and Blood Institute (NHLBI) and the National
Institute of Allergy and Infectious Diseases (NIAID) convened a Working Group
of investigators on April 4-5, 2002, in Bethesda, Maryland. This Working Group
brought together experts to explore both basic science and clinical application
research opportunities of antimicrobial strategies in the prevention and treatment
of major infections following cardiac surgery. The following recommendations were made to NHLBI
and NIAID: - Continue the standardization efforts that have been
undertaken by the NHLBI such as validation of the accuracy of the analytical methods,
utilization of the primary and secondary reference materials developed and validated
under the NHLBI LP(a) contract and pursue a common approach to express LP(a) values
in all studies.
- Promote more basic research to understand the fundamental
functions and mechanism of actions of LP(a) as well as the mechanisms of LP(a)
lowering.
- Encourage the development of animal models to study LP(a).
-
Support large clinical and epidemiological studies, performed with validated analytical
methods and sound study design to establish the clinical relevance and the predictive
power of LP(a).
- Establish common population-based reference values and
LP(a) values for clinical decision.
- Design and implement a clinical study
to evaluate the clinical usefulness of lowering LP(a) levels.
Working
Group Members- John J. Albers, PhD. Northwest Lipid Research Laboratories,
University of Washington, Seattle
- Kåre Berg, MD, Ullevaal University
Hospital, Department of Medical Genetics, Oslo, Norway
- Celina Edelstein,
BA, The University of Chicago, Lipoprotein Study Unit, Chicago
- Jianglin
Fan, MD, PhD, Chief of Laboratory and Cardiovascular Diseases, Institute of Basic
Medical Sciences, University of Tsukuba, Tsukuba, Japan
- Scott M. Grundy,
MD, PhD, Center for Human Nutrition, University of Texas Southwestern Medical
Center, Dallas
- Helen Hobbs, MD, Departments of Internal Medicine and Molecular
Genetics, University of Texas Southwestern Medical Center, Dallas
- William
B. Kannel, MD, MPH, Department of Medicine, Boston University School of Medicine,
Boston
- Marlys L. Koschinsky, PhD, Department of Biochemistry, Queen's
University, Kingston, ON, Canada
- Gerhard M. Kostner, PhD, Institute of
Medical Biochemistry, University of Graz, Austria
- Peter Kwiterovich, MD,
Lipid Research Atherosclerosis Division, The Johns Hopkins Medical Institutions,
Baltimore
- Santica Marcovina, PhD, ScD, Northwest Lipid Research Laboratories,
University of Washington, Seattle
- Sally P. A. McCormick, PhD, Department
of Biochemistry, University of Otago, Dunedin, New Zealand
- Joel D. Morrisett,
PhD, Department of Medicine, Baylor College of Medicine, The Methodist Hospital,
Houston
- Daniel J. Rader, MD, University of Pennsylvania School of Medicine,
Philadelphia
- Edward Rubin, MD, Genome Sciences Department, Lawrence Berkeley
National Laboratory, Berkeley
- Frank M. Sacks, MD, Harvard School of Public
Health, Boston
- Ernst Schaefer, MD, Tufts University School of Medicine,
New England Medical Center Lipid Metabolism Laboratory, Boston
- Armin Steinmetz,
MD, St. Nikolaus Stiftshospital GmbH, Teaching Hospital University of Bonn, Andernach,
Germany
- Gerd Utermann, MD, Institute for Medical Biology and Genetics,
University of Innsbruck, Austria
- Arnold von Eckardstein, MD, Institute
of Clinical Chemistry, University and University Hospital, Zurich, Switzerland
|